RxDoctor Payments DataLook up a doctor →

Mark Hendrixson, MD

Medical Oncology · Crossville, TNNPI 1457469223

Payments from drug & device makers

$11,635in general payments, 2019–2025

Across 578 payments — averaging $20.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novartis$1K
  • Johnson & Johnson$664
  • E.r. Squibb & Sons, L.L.C.$622
  • Daiichi Sankyo Inc.$483
  • Takeda Pharmaceuticals U.S.A., Inc.$469
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$11,10795%
  • Education$5285%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)63$1,309
Novartis55$1,145
Johnson & Johnson(2 entities)31$664
E.r. Squibb & Sons, L.L.C.41$622
Daiichi Sankyo Inc.23$483
Takeda Pharmaceuticals U.S.A., Inc.20$469
Merck21$388
Pfizer20$361
Bayer18$340
Bristol Myers Squibb16$308
Lilly USA, LLC16$296
Sanofi12$288
Amgen16$279
Pharmacyclics LLC, An Abbvie Company15$270
Eisai Inc.12$258
Incyte Corporation11$248
GSK11$231
Regeneron Healthcare Solutions, Inc.8$209
Exelixis Inc.10$191
Seagen Inc.5$169
Adaptive Biotechnologies Corporation10$160
AbbVie7$151
Rigel Pharmaceuticals, Inc.5$149
Tersera Therapeutics LLC7$148
EMD Serono, Inc.8$136
Astellas Pharma US Inc6$133
Mirati Therapeutics, Inc.4$132
AVEO Pharmaceuticals, Inc.4$128
Ipsen Biopharmaceuticals, Inc5$120
Jazz Pharmaceuticals Inc.6$99
Pharmacosmos Therapeutics Inc.5$99
Taiho Oncology, Inc.4$95
Pharmaessentia USA Corporation4$89
Karyopharm Therapeutics Inc.5$88
Kyowa Kirin, Inc.4$82
Genentech USA, Inc.5$80
EUSA Pharma (US) LLC3$77
Genmab U.S., Inc.3$74
Beone Medicines USA, Inc.3$72
Array Biopharma Inc4$71
Gilead(2 entities)5$71
Boehringer Ingelheim3$64
Servier Pharmaceuticals LLC2$53
Legend Biotech USA Inc.2$49
Sobi, Inc2$48
Beigene USA, Inc.2$42
AMAG Pharmaceuticals, Inc.3$38
Spectrum Pharmaceuticals Inc.2$35
Tesaro, Inc.2$34
Geron Corporation2$33
Agios Pharmaceuticals, Inc.2$30
Tempus AI, Inc1$29
Dova Pharmaceuticals2$27
Celltrion USA Inc.1$26
Accord Healthcare, Inc.1$23
Puma Biotechnology, Inc.2$22
Cycle Pharmaceuticals Inc1$22
Deciphera Pharmaceuticals Inc.1$20
Sun Pharmaceutical Industries Inc.1$19
Acceleron Pharma, Inc.1$18

How this compares

$11,635 in reported general payments places this provider in the 50th percentile of 101 medical oncology providers in Tennessee.

See all medical oncology providers in Tennessee

Medicare billing

Part B allowed, 2024
$2,240,149
Medicare patients
491
Services billed
213,225

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate22$410,749
ImbruvicaIbrutinib22$359,023
NubeqaDarolutamide27$356,820
CalquenceAcalabrutinib Maleate15$227,070
VerzenioAbemaciclib23$172,223
Somatuline DepotLanreotide Acetate12$116,245
EnhertuFam-Trastuzumab Deruxtecn-Nxki15$116,193
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5033$102,150
SprycelDasatinib13$83,255
ProcritEpoetin Alfa12$52,201
MvasiBevacizumab-Awwb22$43,100
Evenity (2 Syringes)Romosozumab-Aqqg12$27,844
EliquisApixaban16$9,632
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$7,887
XareltoRivaroxaban12$6,396

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$248$410,74922 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$270$359,02322 claims
BayerNubeqa$340$356,82027 claims
AstraZenecaCalquence, Breztri Aerosphere$1,309$234,95728 claims
Lilly USA, LLCVerzenio$296$172,22323 claims
Ipsen Biopharmaceuticals, IncSomatuline Depot$120$116,24512 claims
Daiichi Sankyo Inc.Enhertu$483$116,19315 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$469$102,15033 claims
E.r. Squibb & Sons, L.L.C.Sprycel$622$83,25513 claims
AmgenMvasi, Evenity (2 Syringes)$279$70,94534 claims
Johnson & JohnsonProcrit, Xarelto$664$58,59724 claims
PfizerEliquis$361$9,63216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 101 medical oncology providers in Tennessee.

Other medical oncology in Crossville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →